Italy · Delayed Price · Currency is EUR GVS S.p.A. Earnings Call Transcripts
Fiscal Year 2026
-
Guidance for 2026–2028 is raised, with mid-single-digit organic growth and EBITDA margin expansion to 27% by 2028. Strategic focus is on organic growth, innovation, and operational excellence across all divisions, with no M&A planned and leverage targeted at 1.0x. Product innovation and market share gains in MedTech, Safety, and hydrogen membranes are key growth drivers.
-
Sales grew 3.3% year-over-year to EUR 215 million, with EBITDA up 2.2% and margin expansion to 25.7%. All divisions posted organic growth, led by transfusion medicine and safety, while guidance for low single-digit growth and margin improvement is reaffirmed amid ongoing geopolitical caution.
-
Q1 2026 saw 3.9% organic revenue growth to €105 million, with adjusted EBITDA margin up 57 bps and net income at €10.7 million. Healthcare, Life Science, and Safety divisions led growth, while Mobility stabilized. Guidance remains for low single-digit sales growth and margin expansion.
Fiscal Year 2025
-
Sales grew 2% year-over-year excluding FX, with adjusted EBITDA up 3% and margin at 25.2%. Guidance for 2026 is low single-digit growth, 20-50 bps EBITDA margin improvement, and a leverage ratio of 1.8, amid ongoing FX and raw material risks.
-
Healthcare and life science and safety divisions delivered strong growth, while mobility lagged. Adjusted EBITDA margin and net income improved year-over-year, with guidance for continued margin expansion and cash generation in Q4. FX, US dialysis, and working capital were key headwinds.
-
Record EBITDA and margin expansion achieved, driven by core MedTech and Safety growth, price increases, and operational improvements. Guidance for mid-high single-digit revenue growth and further margin gains is confirmed, with strong cash generation and dividend planned by year-end.
-
Q1 sales grew 3.2% to EUR 107 million, with EBITDA up 6.1% and net income up 21.6%. Exceptional events delayed some sales to Q2, but guidance for mid-high single-digit growth and improved margins is confirmed. Leverage is targeted below 2 by year-end.
Fiscal Year 2024
-
Revenue rose 1.5% to €430M, with EBITDA up 10% and net income up 52%. 2025 guidance targets mid-high single digit growth, margin expansion, and leverage below 2x, with Transfusion Medicine integration and new products as key drivers.
-
Revenue grew nearly 4% year-over-year with EBITDA margin up 220 bps to 24.3%, driven by strong Healthcare & Safety segments. Leverage ratio fell to 2.3, and 2024 guidance for growth and margin improvement is confirmed despite ongoing challenges in Energy & Mobility.
-
Revenue grew 1.6% year-over-year to €250 million, with adjusted EBITDA up 11% and margin at 24.2%. Health and Safety led growth, while Energy and Mobility faced delays but expects recovery. Guidance for sales and margin was raised, with strong cash generation and a stable outlook.